DOXYLAMINE SUCCINATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Doxylamine Succinate, and when can generic versions of Doxylamine Succinate launch?
Doxylamine Succinate is a drug marketed by Copley Pharm, LNK, Perrigo, Quantum Pharmics, Actavis Labs Fl Inc, Bionpharma, Endo Operations, and Mylan Pharms Inc. and is included in nine NDAs.
The generic ingredient in DOXYLAMINE SUCCINATE is doxylamine succinate; pyridoxine hydrochloride. There are fourteen drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the doxylamine succinate; pyridoxine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Doxylamine Succinate
A generic version of DOXYLAMINE SUCCINATE was approved as doxylamine succinate; pyridoxine hydrochloride by ACTAVIS LABS FL INC on August 19th, 2016.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DOXYLAMINE SUCCINATE?
- What are the global sales for DOXYLAMINE SUCCINATE?
- What is Average Wholesale Price for DOXYLAMINE SUCCINATE?
Summary for DOXYLAMINE SUCCINATE
US Patents: | 0 |
Applicants: | 8 |
NDAs: | 9 |
Finished Product Suppliers / Packagers: | 31 |
Raw Ingredient (Bulk) Api Vendors: | 95 |
Clinical Trials: | 6 |
Patent Applications: | 1,394 |
DailyMed Link: | DOXYLAMINE SUCCINATE at DailyMed |
Recent Clinical Trials for DOXYLAMINE SUCCINATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Luoyang Hospital of TCM | Phase 3 |
Jiamusi Maternal and Child Health Hospital | Phase 3 |
Xuzhou Central Hospital | Phase 3 |
Pharmacology for DOXYLAMINE SUCCINATE
Drug Class | Antihistamine |
Mechanism of Action | Histamine Receptor Antagonists |